StockData
Structure Therapeutics Inc. logo

Structure Therapeutics Inc. (GPCR) company profile

GPCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$18.17−0.40 (-2.15%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

About Structure Therapeutics

Pharmaceutical Preparations, SIC 2834

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral small molecule therapeutics for chronic diseases with unmet medical need. Utilizing a structure-based drug discovery platform and computational chemistry, the enterprise targets G-protein coupled receptors across metabolic, cardiovascular, and pulmonary conditions. Its lead product candidate is aleniglipron (GSBR-1290), an oral GLP-1 receptor agonist in clinical trials for obesity and overweight management. The company is also advancing oral small molecule amylin receptor agonists, including ACCG-2671 and ACCG-3535, alongside discovery-stage programs targeting GIP, glucagon, and APJ receptors for use as monotherapies or fixed-dose combinations for individuals living with metabolic and chronic disorders.

The company maintains a global presence with clinical trials conducted across multiple sites in the United States and Japan. Its manufacturing infrastructure provides a production capacity of 6,000 tons per year of aleniglipron. The provided text does not state the company's specific headquarters location.

Summary of the business section of Structure Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Structure Therapeutics Inc.
Headquarters
South San Francisco, CA
Address
601 Gateway Blvd Suite 900 94080
Phone
(650) 457-1978
Employees
220, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
E9
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
GPCR
Exchange
Nasdaq
IPO date
Feb 6, 2023
Shares outstanding
214M, Jul 31, 2026
Public float
$834.90M, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1888886
CUSIP
86366E106
ISIN
US86366E1064
FIGI
BBG01CBVHLW1
Share class FIGI
BBG01CBVHMQ6
EIN
98-1480821

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Raymond C. StevensCHIEF EXECUTIVE OFFICER, Director2,956,179
Crespo Blas CollCHIEF MEDICAL OFFICER258,228
Xichen LinCHIEF SCIENTIFIC OFFICER228,960
John Joseph BerriosChief Commercial Officer140,766
Matthew LangCOO & GC184,614
Jun YoonCHIEF FINANCIAL OFFICER2,956,242
Yingli MaCHIEF TECHNOLOGY OFFICER139,917
Ashley HallChief Development Officer155,187
Eric DobmeierDirector–
Angus C. RussellDirector–
Ted W. LoveDirector–
Daniel G. WelchDirector123,508
Sharon TetlowDirector–
Joanne WaldstreicherDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$8.43M$36.23M$3.05M$268$135
FY2024$5.74M$1.74M$3.57M$104$101
FY2023$7.39M$22.06M$2.17M$157$102

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Raymond Stevens
Chief Executive Officer and Director
$672.09K$2.39M$4.85M$508.87K$14.00K$8.43M+47%
Jun Yoon
Chief Financial Officer
$530.53K$1.19M$2.42M$309.08K$10.53K$4.47M+59%
Blai Coll
Chief Medical Officer
$492.81K$820.87K$1.67M$253.15K$14.00K$3.25M-6%
Xichen Lin
Chief Scientific Officer
$505.31K$567.15K$1.15M$257.10K–$2.48M-33%
Yingli Ma
Chief Technology Officer
$429.77K$447.73K$908.79K$212.59K–$2.00M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 6, 2023
Offer price
$15.00
Securities offered
10,740,000
Gross proceeds
$161.10M
Exchange
Nasdaq
First trading day
Feb 3, 2023
First-day close
$26.00+73.3%
Lock-up ends (est.)
Aug 2, 2023

“The initial public offering price is $15.00 per ADS.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 220 full-time employees, 75 of whom have a Ph.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 14, 2023Late filingNotification of late filing
Jun 5, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 6, 2023IPOInitial public offering priced (424B4 prospectus)
Jan 30, 2023ListingRegistration of securities on an exchange (Form 8-A)
May 13, 2022Name changeName changed from ShouTi Inc. to Structure Therapeutics Inc.

See a number that looks wrong?